General Information
Lilly DM2 GBGJ
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses versus Placebo in Patients with Type 2 Diabetes on Metformin Monotherapy
| Protocol | H9X-MC-GBGJ |
|---|---|
| Identifier | Site Number: 117 PO # 4900570260 |
| UID | e27e5110-ec86-43a8-8c0f-5e50e9c91be2 |
| Status | Done - Archived |
| Phase | 2 |
| Category | Diabetes Type 2 |
| Launch Year | 2016 |
| NCT Number | - |
| Created | 2016-10-06 10:08 |
| Last Updated | 2016-10-06 10:08 |
Description
No description provided.
Comment
PCRS
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2017-01-20 | No |
| Enrollment Open | 2016-12-19 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2016-11-30 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2017-11-07 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Rocha, Luis | LRocha | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Eli Lilly and Company |
|---|---|
| Division | Lilly |
| Team | Lilly |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Inventiv Health Clinical, LLC |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
